Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RAP-219

Small molecule · developed by Rapport Therapeutics

Phase 3 Most advanced trial
RAPP Developer
1 Registered trials

What is RAP-219?

RAP-219 is an orally administered tablet studied in focal seizures and focal epilepsy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Rapport Therapeutics Inc. (RAPP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07563881 Phase 3 Focal Seizure Recruiting RAPP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

EpilepsyFocal EpilepsyFocal Seizure

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the RAPP page.

Follow RAPP, the company behind RAP-219

See RAPP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RAPP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.